DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/nn4wjh/epicast_report) has announced the addition of the "EpiCast Report: Hepatocellular Carcinoma - Epidemiology Forecast to 2024" report to their offering.
The Hepatocellular Carcinoma (HCC) EpiCast Report provides an overview of the risk factors and global trends of HCC in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed incident cases and five-year diagnosed prevalent cases of HCC in these markets. The diagnosed incident cases of HCC are segmented by age (30-39 years, 40-49 years, 50-59 years, 60-69 years, and 70-79 years, =80 years), sex, BCLC stage at diagnosis, and comorbidity with HBV or HCV.
The overall increase in the incidence of HCC in the 7MM was mostly driven by population changes, as GlobalData epidemiologists observed very little historical changes in the incidence of HCC. During the forecast period, changes in alcohol use/abuse among men and women may impact the incidence of HCC in the US and UK. Furthermore, the high prevalence of HCV in Italy and Japan will continue to contribute to HCC incidence.
Key Topics Covered:
1 Tables & Figures
2 Introduction
3 Epidemiology
4 Appendix
For more information visit http://www.researchandmarkets.com/research/nn4wjh/epicast_report
